Equities

Beijing Kawin Technology Share-Holding Co Ltd

688687:SHH

Beijing Kawin Technology Share-Holding Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)22.44
  • Today's Change-0.12 / -0.53%
  • Shares traded863.69k
  • 1 Year change+0.67%
  • Beta1.5797
Data delayed at least 15 minutes, as of Jul 30 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Beijing Kawin Technology Share-Holding Co Ltd is a China-based company principally engaged in the production and sales of therapeutic drugs in the viral disease field, and the research and development of innovative drugs. The Company's recombinant human interferon α2b and compound glycyrrhizin drugs are applied to treat viral diseases. The Company mainly distributes its products within domestic market.

  • Revenue in CNY (TTM)1.43bn
  • Net income in CNY117.53m
  • Incorporated2008
  • Employees584.00
  • Location
    Beijing Kawin Technology Share-Holding Co LtdNo. 6 Rongjing East Street, EconomicTechnological Development ZoneBEIJING 100176ChinaCHN
  • Phone+86 1 087120888
  • Fax+86 1 067872896
  • Websitehttps://www.kawin.com.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Xinjiang Bai Hua Cun Pharma Tech Co Ltd384.44m26.95m2.15bn787.0079.542.95--5.590.07080.07081.011.910.3671.381.79488,492.202.57-4.593.60-6.2448.3824.097.01-18.401.44--0.0021--5.54-2.50137.33---21.00--
Hinova Pharmaceuticals Inc0.00-266.00m2.39bn179.00--1.80-----2.69-2.690.0013.390.00105.68--0.00-17.03-31.86-18.39-37.18-------25,578.2411.83--0.0097---100.00--2.44--124.37--
Shanghai Aladdin Biochemical Tech Co Ltd414.81m85.68m2.60bn566.0025.992.46--6.260.36020.36021.383.800.28030.38989.21732,874.105.798.836.209.6160.0861.4920.6626.858.00--0.251945.716.5519.36-7.489.9531.41--
Bide Pharmatech Co Ltd1.10bn98.72m2.63bn846.0026.591.28--2.381.091.0912.1422.500.45851.094.761,302,686.004.06--4.62--38.38--8.86--5.29--0.0416--30.94---24.94------
Jiangsu Yahong Meditech Co Ltd38.05m-420.35m2.81bn394.00--1.22--73.85-0.7375-0.73750.06684.030.01423.053.7696,573.63-15.68-15.80-16.54-16.4877.7255.32-1,106.10-9,445.9111.34--0.0684--52,594.79---62.42--64.28--
Qingdao Vland Biotech INC1.25bn82.87m3.02bn1.57k35.931.76--2.410.33260.33265.026.810.44313.424.33797,663.403.805.785.777.8945.3846.138.5810.340.8387149.270.289633.593.078.0515.56-0.650724.68-6.89
Shanghai Medicilon Inc1.17bn-172.33m3.80bn2.60k--1.54--3.23-1.24-1.249.1118.340.42056.631.64451,437.20-6.179.34-7.9711.7312.4836.71-14.6814.932.63--0.122920.18-17.6833.26-109.82--23.60--
Beijing Kawin Technol Sha-hld Co Ltd1.43bn117.53m3.86bn584.0031.952.13--2.690.70610.70618.6110.600.62641.664.422,451,945.006.115.317.696.7682.3586.029.768.103.25--0.080943.8221.7314.8739.7121.0425.01--
HitGen Inc409.13m64.05m3.87bn452.0060.332.81--9.460.16010.16011.023.440.2416.704.84905,165.503.774.634.025.1051.4658.8915.6620.6614.48360.770.14219.1412.6419.6961.16-1.96-6.12--
InventisBio Co Ltd194.13m-249.28m4.09bn221.00--2.11--21.06-0.4289-0.42890.33483.350.0898--1.96878,429.50-11.53---12.26--97.85---128.41------0.0054------41.26------
Beijing Sun-Novo Pharma Research Co Ltd951.95m209.57m4.11bn1.37k19.604.05--4.321.871.878.509.060.546526.191.77694,854.3011.7012.9919.1321.7059.1053.9321.4021.341.7745.000.372110.7437.7647.2218.0854.9034.77--
GemPharmatech Co Ltd638.97m157.34m4.36bn1.51k27.722.05--6.830.38380.38381.565.200.26174.112.36424,282.406.449.457.2811.1366.4370.2124.6228.164.68--0.059214.6820.4563.48-3.48--141.38--
Data as of Jul 30 2024. Currency figures normalised to Beijing Kawin Technology Share-Holding Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

29.09%Per cent of shares held by top holders
HolderShares% Held
E Fund Management Co., Ltd.as of 31 Dec 202314.63m12.85%
Zhong Geng Fund Management Co. , Ltd.as of 31 Dec 20233.93m3.45%
Fullgoal Fund Management Co., Ltd.as of 31 Dec 20232.82m2.48%
China Universal Asset Management Co., Ltd.as of 31 Dec 20232.54m2.23%
Golden Eagle Asset Management Co., Ltd.as of 31 Dec 20232.18m1.92%
Zhong Ou Asset Management Co., Ltdas of 31 Dec 20232.02m1.78%
Bosera Asset Management Co., Ltd.as of 31 Dec 20231.78m1.57%
China Southern Asset Management Co., Ltd.as of 31 Dec 20231.18m1.04%
HuaAn Fund Management Co., Ltd.as of 31 Dec 20231.02m0.89%
Bank of China Investment Management Co., Ltd.as of 31 Dec 20231.01m0.89%
More ▼
Data from 31 Dec 2023 - 24 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.